An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease

Anti–tumor necrosis factor (anti-TNF) therapy resistance is a major clinical challenge in inflammatory bowel disease (IBD), due, in part, to insufficient understanding of disease-site, protein-level mechanisms. Although proteomics data from IBD mouse models exist, data and phenotype discrepancies contribute to confounding translation from preclinical animal models of disease to clinical cohorts. We developed an approach called translatable components regression (TransComp-R) to overcome interspecies and trans-omic discrepancies between mouse models and human subjects. TransComp-R combines mouse proteomic data with patient pretreatment transcriptomic data to identify molecular features discernable in the mouse data that are predictive of patient response to therapy. Interrogating the TransComp-R models revealed activated integrin pathway signaling in patients with anti–TNF-resistant colonic Crohn’s disease (cCD) and ulcerative colitis (UC). As a step toward validation, we performed single-cell RNA sequencing (scRNA-seq) on biopsies from a patient with cCD and analyzed publicly available immune cell proteomics data to characterize the immune and intestinal cell types contributing to anti-TNF resistance. We found that ITGA1 was expressed in T cells and that interactions between these cells and intestinal cell types were associated with resistance to anti-TNF therapy. We experimentally showed that the α1 integrin subunit mediated the effectiveness of anti-...

Source: Signal Transduction Knowledge Environment - August 3, 2020 Category: Science Authors: Brubaker, D. K., Kumar, M. P., Chiswick, E. L., Gregg, C., Starchenko, A., Vega, P. N., Southard-Smith, A. N., Simmons, A. J., Scoville, E. A., Coburn, L. A., Wilson, K. T., Lau, K. S., Lauffenburger, D. A. Tags: STKE Research Articles Source Type: news